Chair: David Pyott, Chairman & CEO, Allergan, Inc.
Staff Contact: Joseph Damond, Senior Vice President, International Affairs, email@example.com
Description: The committee oversees, in conjunction with other relevant BIO committees, BIO’s international work plan objectives to foster an environment conducive to biotechnology, re-shape the debate on IP and pro-innovation policies, and influence regulatory reform and harmonization discussions in key international markets. The committee’s jurisdiction includes oversight of BIO’s International Affairs Initiative, international organization matters (e.g., WHO, WTO, WIPO, APEC, OECD), international advocacy and education programs, international studies, and coordinating efforts of foreign peer organizations.
David Pyott, Chairman & CEO, Allergan, Inc.
Julie Gerberding, President, Merck Vaccines, Merck & Co, Inc.
Roch Doliveux, Chairman & CEO, UCB SA
Geno Germano, President & General Manager, Specialty Care Business Unit, Pfizer, Inc.
Scott Koenig, President & CEO, MacroGenics, Inc.
David Meeker, Executive Vice President, Genzyme Corporation: A Sanofi Company
Arlene Morris, Cheif Executive Officer, Syndax, Inc.
Francois Nader, President & CEO, NPS Pharmaceuticals, Inc.
Nicholas Nicolaides, President & CEO, Morphotek, Inc.
Ana Protopapas, President, Millennium: The Takeda Oncology Company
Stephan Tanda, Managing Board Member, DSM Pharmaceutical Products
Bradford Zakes, Chief Executive Officer, Cerevast Therapeutics, Inc.
Neil Warma, President & CEO, Opexa Therapeutics, Inc.